Genetics of thick tumors in head and neck cancers
Not Applicable
- Conditions
- Health Condition 1: C14- Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx
- Registration Number
- CTRI/2024/04/065199
- Lead Sponsor
- DY Patil University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients of oral cancers undergoing surgery in our department
Exclusion Criteria
Palliative resection and metastatic patients
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To find various genetic mutation or molecular changes found in head and neck cancer cells having depth of invasion more than 10 mmTimepoint: Patient will be accessed, at presentation, after completion of treatment, at 3 months, at 6 months, at 12 months and at 2nd year. <br/ ><br>All follow ups will be as per standard protocol for disease follow up and no extra follow for study will be done unless indicated clinically. <br/ ><br>Genetic analysis will be done on tumor tissue blocks once histopathology report of tumor is available.
- Secondary Outcome Measures
Name Time Method To find any targetable molecular change associated with head and neck cancers having depth of invasion more than 10 mmTimepoint: At the end of 2 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways drive tumor thickness in C14 head and neck malignancies with >10mm depth of invasion?
How do genetic alterations in C14 HNSCC affect response to standard-of-care therapies like cisplatin or cetuximab?
Which biomarkers correlate with >10mm depth of invasion in oral cavity and pharyngeal cancers for patient stratification?
What adverse event patterns are observed in head and neck cancer patients with thick tumors and TP53 mutations?
Are there existing targeted therapies or combinations addressing EGFR overexpression in C14 malignancies with deep invasion?